Doximity (DOCS) 주식 개요
는 미국 내 의료 전문가를 위한 디지털 플랫폼을 운영하고 있습니다. 자세히 보기
DOCS Community Fair Values
Create NarrativeSee what 92 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$33.7
FV
35.0% 저평가 내재 할인율17.00%
Revenue growth p.a.
55
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
Doximity, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$21.89 |
| 52주 최고가 | US$76.51 |
| 52주 최저가 | US$17.15 |
| 베타 | 1.21 |
| 1개월 변동 | 0.14% |
| 3개월 변동 | -14.79% |
| 1년 변동 | -62.21% |
| 3년 변동 | -33.24% |
| 5년 변동 | -58.64% |
| IPO 이후 변동 | -58.70% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jul 21
DOCS: Clinical AI Safety Leadership Will Support Higher Future Earnings Power
The analyst fair value estimate for Doximity has been reset from $55.00 to $36.89 after multiple firms trimmed price targets, citing concerns about slower core growth, heavier AI investment weighing on margins, and rising competitive and execution risks. Analyst Commentary Recent Street research on Doximity reflects a reset in expectations around growth, profitability, and competitive positioning, particularly as the company leans into heavier AI investment and faces questions about the durability of its core advertising business.
내러티브 업데이트 • Jul 07
DOCS: AI Spending And Competitive Pressures Will Test Healthcare Moat And Reengagement Potential
Doximity's analyst price target has been trimmed as fair value and the assumed future P/E move lower, with analysts citing weaker revenue visibility, heavier AI spending, and rising competitive pressures around digital pharma marketing and healthcare AI tools. Analyst Commentary Recent Street research on Doximity points to a more cautious stance, with many firms cutting price targets and revisiting growth expectations after the latest earnings reports and long term guidance.Recent updates
내러티브 업데이트 • Jul 21
DOCS: Clinical AI Safety Leadership Will Support Higher Future Earnings Power
The analyst fair value estimate for Doximity has been reset from $55.00 to $36.89 after multiple firms trimmed price targets, citing concerns about slower core growth, heavier AI investment weighing on margins, and rising competitive and execution risks. Analyst Commentary Recent Street research on Doximity reflects a reset in expectations around growth, profitability, and competitive positioning, particularly as the company leans into heavier AI investment and faces questions about the durability of its core advertising business.내러티브 업데이트 • Jul 07
DOCS: AI Spending And Competitive Pressures Will Test Healthcare Moat And Reengagement Potential
Doximity's analyst price target has been trimmed as fair value and the assumed future P/E move lower, with analysts citing weaker revenue visibility, heavier AI spending, and rising competitive pressures around digital pharma marketing and healthcare AI tools. Analyst Commentary Recent Street research on Doximity points to a more cautious stance, with many firms cutting price targets and revisiting growth expectations after the latest earnings reports and long term guidance.Seeking Alpha • Jun 30
Doximity: Everyone Is Focused On The Guidance While Missing The Valuation And AI Stories
Summary Doximity issued conservative FY2027 guidance, projecting 4% revenue growth and a 49% adjusted EBITDA margin, triggering a post-earnings stock selloff. I view the selloff as a temporary dislocation and a compelling buying opportunity for value investors given DOCS's resilient core platform usage. Management emphasized record physician engagement and continued dominance of DOCS's core products despite macroeconomic and regulatory headwinds. AI tools, particularly AI Search and Scribe, are rapidly scaling and positioned as DOCS's next major revenue driver. Read the full article on Seeking Alpha내러티브 업데이트 • Jun 23
DOCS: AI Investment Year And Healthcare Moat Set To Support Reengagement
The updated Doximity analyst price target edges up slightly to $25.42, as analysts balance concerns about slower digital advertising growth, tougher competition, and heavier AI investment against a still supportive longer term rationale. This is reflected in a modestly higher fair value and P/E assumption.
새로운 내러티브 • Jun 13
High physician usership and impressive AI tools
What I like about Doximity is that there really is a very high viewership / user base of active practicing Physicians in the US and that is not invaluable and definitely could be monetized perhaps more efficiently. I also think that Doximity offers a lot of interesting tools for Physicians a lot of which you’re free and really marketed towards I think Physicians who are more in private practice.내러티브 업데이트 • Jun 07
DOCS: Healthcare Moat And AI Investment Year Will Drive Future Engagement
Analyst price targets for Doximity have been reset lower, with the internal fair value estimate moving from $37.77 to $25.15 as analysts factor in slower projected revenue growth, softer profit margins, and a reduced future P/E multiple amid industry wide concerns about digital ad spending, rising competition, and uncertain payoffs from heavier AI investment. Analyst Commentary Street research has turned more cautious on Doximity following its recent results and fiscal 2027 outlook, with many firms cutting price targets and, in several cases, downgrading ratings.
내러티브 업데이트 • May 23
DOCS: Heavier AI Spending And Competition Will Drive A Cautious Bearish Outlook
Analysts cut the Doximity fair value estimate from $25.00 to $18.00, citing a wave of price target reductions and ratings downgrades that point to slower expected revenue growth, thinner margins, rising AI investment costs, and tougher digital advertising and healthcare IT competition. Analyst Commentary Street research around Doximity has shifted decisively more cautious, with a cluster of downgrades and lower price targets following the most recent earnings and long term outlook.내러티브 업데이트 • May 09
DOCS: AI Suite And Platform Stickiness Will Support Higher Future Earnings Power
Analysts trimmed their Doximity fair value estimate to $55.00 from $56.00, reflecting reduced revenue growth assumptions, partly offset by expectations for slightly higher profit margins and a marginally richer future P/E multiple following a series of recent price target cuts and mixed rating changes across the Street. Analyst Commentary Recent Street research on Doximity has been mixed, with a cluster of price target cuts and rating changes alongside a handful of more constructive views.내러티브 업데이트 • Apr 21
DOCS: Healthcare Moat And AI Tools Will Support Future Engagement
The updated analyst price target for Doximity reflects a modest fair value reduction of about $1.77 per share, as analysts factor in weaker revenue growth visibility highlighted in several recent downgrades and target cuts, while also noting resilient margins and interest in the company’s AI tool suite. Analyst Commentary Recent research on Doximity presents a mix of optimism around the platform and its AI tools, alongside concern about the visibility and durability of revenue growth.내러티브 업데이트 • Apr 07
DOCS: Rebased Sentiment And Healthcare Moat Will Support Future Engagement
The updated analyst price target for Doximity moves from about $63.57 to roughly $39.55. This reflects lower modeled revenue growth, profit margins and future P/E multiples, even as several firms highlight the platform's network effects, AI tools and healthcare marketing traction as key long term strengths.내러티브 업데이트 • Mar 24
DOCS: AI Tools And Buybacks Will Shape A Cautious Balanced Outlook
Analysts held the Doximity fair value estimate steady at $25.00, while modestly adjusting assumptions after mixed but generally constructive price target moves that highlight interest in the platform's AI tools, network effects, and healthcare marketing exposure. Analyst Commentary Recent Street research on Doximity reflects a split view, with some firms highlighting the medical AI tool suite, network effects and healthcare marketing exposure, while others reset expectations through lower price targets and more neutral ratings.내러티브 업데이트 • Mar 09
DOCS: AI Tools And Share Buybacks Will Drive Shares Higher
Doximity's updated fair value estimate has decreased to $56.00 from $68.90, reflecting analysts' reduced price targets from several firms, alongside ongoing support for the company's AI tools and healthcare marketing position. Analyst Commentary Street research on Doximity has been mixed, but there is a clear cluster of bullish analysts who see support for the story in healthcare marketing, AI tools and the company’s position with U.S. physicians.내러티브 업데이트 • Feb 23
DOCS: AI Suite And Share Buybacks Will Shape A More Balanced Outlook
The analyst fair value estimate for Doximity has been revised to $25 from $50, reflecting a wave of reduced price targets across several firms, even as some analysts highlight potential from the company’s AI tools and broader healthcare marketing ecosystem. Analyst Commentary Recent research on Doximity shows a split tape, with some firms cutting price targets sharply while others highlight potential upside tied to the company’s tools and healthcare marketing position.내러티브 업데이트 • Feb 09
DOCS: Pharma Ad Shift And Share Buybacks Will Drive Shares Higher
Analysts have reduced their Doximity fair value estimate from about US$83 to roughly US$69. This reflects updated expectations for more moderate revenue growth, slightly lower profit margins and a reduced future P/E multiple, even as several firms highlight the company’s strong position in digital healthcare marketing and its expanding product tools.분석 기사 • Feb 06
Doximity, Inc.'s (NYSE:DOCS) Popularity With Investors Under Threat As Stock Sinks 27%
To the annoyance of some shareholders, Doximity, Inc. ( NYSE:DOCS ) shares are down a considerable 27% in the last...내러티브 업데이트 • Jan 26
DOCS: Rebased Sentiment And Strong Moat Will Support Future Engagement
Narrative Update on Doximity The analyst fair value estimate for Doximity has been adjusted from US$65.25 to about US$63.57 as analysts factor in lower target prices, along with continued confidence in the company's moat, market share gains, and higher reported ROI compared with other digital healthcare marketing platforms. Analyst Commentary Recent research on Doximity highlights a mix of optimism and caution as analysts update ratings and price targets while reassessing growth, execution, and risk pricing.내러티브 업데이트 • Jan 11
DOCS: Rebased Sentiment And Budget Shifts Will Support Stronger Engagement
Our updated analyst price target framework for Doximity moves fair value from US$71.11 to US$65.25 as analysts recalibrate growth, discount rate and forward P/E assumptions, while still pointing to strengthening platform engagement and expanding tools such as OpenEvidence, as well as what several describe as a defensible competitive position in healthcare professional marketing. Analyst Commentary Recent Street research on Doximity reflects a mix of optimism around the core franchise and its tools such as OpenEvidence, alongside a more cautious reset on valuation and competitive risk.내러티브 업데이트 • Dec 26
DOCS: Budget Flush And Pharma Ad Shift Will Drive Shares Higher
We modestly raised our Doximity price target to $83.00 per share from $62.00, as analysts highlight improving long term growth visibility, accelerating video driven revenue momentum, and an increasingly compelling risk reward profile following the recent pullback, despite ongoing debate around pharma digital ad trends. Analyst Commentary Bullish analysts are increasingly highlighting Doximity as a high conviction idea following the post earnings selloff, pointing to a more attractive entry point relative to its vertical software peers.내러티브 업데이트 • Dec 12
DOCS: Budget Flush And Ad Shift Will Drive Shares Higher
Analysts have lifted their Doximity fair value estimate to $83.00 from $78.58, reflecting stronger expected revenue growth and improving long term growth visibility, which they believe more than offset lower margin assumptions and a higher required return. Analyst Commentary Bullish analysts highlight that the recent pullback in Doximity shares has created a compelling entry point, with the stock now trading at what they view as an unjustified discount to the broader vertical software peer group.분석 기사 • Nov 14
Doximity, Inc. (NYSE:DOCS) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
The Doximity, Inc. ( NYSE:DOCS ) share price has fared very poorly over the last month, falling by a substantial 26...내러티브 업데이트 • Nov 01
DOCS: Pharma Advertising Shift And AI Expansion Will Drive Measured Opportunity And Risks
Analysts have modestly increased their price target for Doximity, raising the estimate from $70.72 to $71.11 per share. They cite stronger revenue momentum, which is supported by recent upgrades and expectations for higher provider-driven growth.내러티브 업데이트 • Oct 18
AI Integration And Telehealth Expansion Will Transform The Healthcare Industry
Analysts have raised their price target for Doximity from $69.50 to $70.72. They cited slightly improved profit margin forecasts and increased confidence in the company’s platform engagement as advertising trends evolve.내러티브 업데이트 • Oct 04
AI Integration And Telehealth Expansion Will Transform The Healthcare Industry
Doximity's analyst price target has increased from $68.67 to $69.50 per share. This change reflects analysts' positive view on strong business momentum, promising AI initiatives, and a conservative outlook for fiscal 2026 revenue growth.내러티브 업데이트 • Sep 13
AI Integration And Telehealth Expansion Will Transform The Healthcare Industry
Doximity’s price target was raised modestly to $68.67 as analysts pointed to robust Q1 results, AI-driven strategy enhancements, and conservative guidance as drivers of sustained business momentum. Analyst Commentary Bullish analysts cite strong Q1 results and upwardly revised guidance as evidence of solid business momentum.분석 기사 • Sep 02
At US$67.94, Is Doximity, Inc. (NYSE:DOCS) Worth Looking At Closely?
Doximity, Inc. ( NYSE:DOCS ) saw a significant share price rise of 32% in the past couple of months on the NYSE...분석 기사 • Aug 15
We Think Doximity's (NYSE:DOCS) Profit Is Only A Baseline For What They Can Achieve
NYSE:DOCS 1 Year Share Price vs Fair Value Explore Doximity's Fair Values from the Community and select yours When...내러티브 업데이트 • Aug 10
AI Integration And Telehealth Expansion Will Transform The Healthcare Industry
Doximity’s fair value outlook has improved as reflected by a higher consensus price target, despite a notable contraction in net profit margin and a rising future P/E multiple signaling higher growth expectations. What's in the News Doximity provided revenue guidance for FY26 of $628–636 million and Q2 FY26 of $157–158 million.분석 기사 • Jul 08
Getting In Cheap On Doximity, Inc. (NYSE:DOCS) Is Unlikely
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 18x, you may...분석 기사 • Jun 23
With EPS Growth And More, Doximity (NYSE:DOCS) Makes An Interesting Case
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...분석 기사 • May 17
At US$52.56, Is Doximity, Inc. (NYSE:DOCS) Worth Looking At Closely?
Let's talk about the popular Doximity, Inc. ( NYSE:DOCS ). The company's shares saw significant share price movement...분석 기사 • May 01
Calculating The Intrinsic Value Of Doximity, Inc. (NYSE:DOCS)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Doximity fair value estimate is US$54.31 With US$56.88 share...분석 기사 • Apr 04
Shareholders Are Optimistic That Doximity (NYSE:DOCS) Will Multiply In Value
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...분석 기사 • Feb 23
What Doximity, Inc.'s (NYSE:DOCS) 28% Share Price Gain Is Not Telling You
Despite an already strong run, Doximity, Inc. ( NYSE:DOCS ) shares have been powering on, with a gain of 28% in the...Seeking Alpha • Feb 10
Doximity Q3 Earnings: Outpacing Even Management's Expectations
Summary I previously rated Doximity, Inc. a buy due to strong Q2 earnings, favorable DCF analysis, and its strategic position in the healthcare industry. Q3 earnings showed continued strength, with DOCS stock up 56% compared to the S&P 500's 2% return since my last analysis. Updated DCF valuation, incorporating management guidance and industry trends, suggests a new price target of $90, indicating 14% upside from today. Doximity's product-market fit remains nearly perfect, with robust revenue growth and efficient cost scaling, supporting a continued buy rating. Read the full article on Seeking Alpha주주 수익률
| DOCS | US Healthcare Services | US 시장 | |
|---|---|---|---|
| 7D | 2.1% | 3.1% | 4.9% |
| 1Y | -62.2% | -31.1% | 21.3% |
수익률 대 산업: DOCS은 지난 1년 동안 -31.1%의 수익을 기록한 US Healthcare Services 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: DOCS은 지난 1년 동안 21.3%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| DOCS volatility | |
|---|---|
| DOCS Average Weekly Movement | 9.2% |
| Healthcare Services Industry Average Movement | 10.0% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
안정적인 주가: DOCS는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: DOCS의 주간 변동성(9%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2010 | 880 | Jeff Tangney | www.doximity.com |
는 미국에서 의료 전문가를 위한 디지털 플랫폼을 운영하고 있습니다. 회원에게 임상 및 전문 콘텐츠를 제공하는 개인화된 뉴스피드를 제공하는 Doximity 플랫폼에는 의학 기사, 임상시험 또는 연구 결과를 소비하기 쉬운 동영상 형식으로 제공하고, 동료 및 동료의 전문적인 업데이트와 업적, 임상 토론, 출판용 Op-Med 기사, 제약 제조업체 및 의료 시스템에서 후원하는 콘텐츠가 포함되어 있습니다. 또한 임상 워크플로우 내에서 근거 기반 의료 정보에 액세스하고 적용할 수 있는 HIPAA 준수 AI 비서인 Ask, HIPAA 준수 AI 기반 임상 문서화 도구인 Scribe, 병원 및 의료 시스템을 위한 원격 의료 도구, 당직 예약 도구인 AMiON 등의 워크플로우 도구를 제공합니다.
Doximity, Inc. 기초 지표 요약
| DOCS 기초 통계 | |
|---|---|
| 시가총액 | US$3.89b |
| 순이익 (TTM) | US$196.05m |
| 매출 (TTM) | US$644.86m |
20.1x
주가수익비율(P/E)6.1x
주가매출비율(P/S)DOCS는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| DOCS 손익계산서 (TTM) | |
|---|---|
| 매출 | US$644.86m |
| 매출원가 | US$70.33m |
| 총이익 | US$574.54m |
| 기타 비용 | US$378.49m |
| 순이익 | US$196.05m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
Aug 06, 2026
| 주당순이익(EPS) | 1.09 |
| 총이익률 | 89.09% |
| 순이익률 | 30.40% |
| 부채/자본 비율 | 0% |
DOCS의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/04 13:55 |
| 종가 | 2026/08/04 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2026/03/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Doximity, Inc.는 26명의 분석가가 다루고 있습니다. 이 중 20명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Vikram Kesavabhotla | Baird |
| Glen Santangelo | Barclays |
| Nisala Weerasuriya | Berenberg |